Fundraising FoxTheradaptive
Frederick, US · Delaware corporation · 3 known investors
Find your way into Theradaptive
Sign up to see every warm intro you have to Theradaptive
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Theradaptive team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.
Founders & leadership
Board
Investors · 3
Funding
SEC filings, press & company announcements$36.2M disclosed across 1 of 4 rounds · 2021–2026
▶$36.2MraisedAug 2026 · 65 investors · BiotechnologyRule 506(b)
- Luis AlvarezExecutive Officer, Director
- David StewartExecutive Officer, Director
- Ted A. MeyersDirector
- George ShanineDirector
- Patrick ZhangDirector
- David HarringtonDirector
- Jeffrey DunnDirector
- Offering amount
- $77.9M
- Amount sold
- $36.2M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Theradaptive.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2020 | $1.1M |
| Department of DefenseDefense Health Program | Phase I | 2017 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Theradaptive do?
- Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.
- Who founded Theradaptive?
- Theradaptive was founded by Luis Alvarez.
- Who are Theradaptive's investors?
- Theradaptive's investors include Horizons Ventures, Maryland TEDCO, TEDCO.
- How much funding has Theradaptive raised?
- Theradaptive has disclosed $36.2M raised across 1 of its 4 known rounds.
- Where is Theradaptive headquartered?
- Theradaptive is headquartered in Frederick, US.